Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (96,426,856)	$ (73,735,953)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	14,912,556	9,150,373
Non-cash research and development license expense		7,155,337
Amortization of debt discount	851,862	491,009
Amortization of operating lease right-of-use asset	802,949
Change in operating lease liability	(922,179)
Loss on extinguishment of debt		1,247,012
Depreciation	45,305	16,482
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(252,929)	(498,897)
Other assets	(5,535)	(177,500)
Accounts payable	(122,341)	371,801
Accrued expenses and other current liabilities	1,731,923	(1,922,716)
Net cash used in operating activities	(79,385,245)	(57,903,052)
Cash flows from investing activities
Purchases of equipment	(307,549)	(25,604)
Net cash used in investing activities	(307,549)	(25,604)
Cash flows from financing activities
Proceeds from issuance of common stock upon financing, net	7,212,367	12,074,999
Proceeds from issuance of term loan		50,000,000
Payment of debt financing costs		(1,102,609)
Repayment of principal on term loan		(21,660,000)
Proceeds from issuance of common stock upon exercise of options	3,310,877	1,010,391
Payments of tax withholdings on stock award	(84,010)
Net cash (used in) provided by financing activities	10,439,234	40,322,781
Net (decrease) increase in cash	(69,253,560)	(17,605,875)
Cash at beginning of period	183,876,453	219,966,167
Cash at end of period	114,622,893	202,360,292
Supplemental disclosures of cash flow information:
Interest paid	$ 3,482,083	1,179,337
Supplemental disclosures of non-cash financing activity:
Issuance of warrants in connection with debt financing		884,216
Common stock issued in connection with license agreement with Pfizer, Inc.		$ 8,000,000